114 related articles for article (PubMed ID: 22520336)
21. Economic analysis of psychosocial group therapy in women with metastatic breast cancer.
Lemieux J; Topp A; Chappell H; Ennis M; Goodwin PJ
Breast Cancer Res Treat; 2006 Nov; 100(2):183-90. PubMed ID: 16773438
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Lux MP; Wöckel A; Benedict A; Buchholz S; Kreif N; Harbeck N; Kreienberg R; Kaufmann M; Beckmann MW; Jonat W; Hadji P; Distler W; Raab G; Tesch H; Weyers G; Possinger K; Schneeweiss A
Onkologie; 2010; 33(4):155-66. PubMed ID: 20389141
[TBL] [Abstract][Full Text] [Related]
23. Assessing the economic burden of breast cancer in a US managed care population.
Barron JJ; Quimbo R; Nikam PT; Amonkar MM
Breast Cancer Res Treat; 2008 May; 109(2):367-77. PubMed ID: 17674201
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs.
Will BP; Le Petit C; Berthelot JM; Tomiak EM; Verma S; Evans WK
Br J Cancer; 1999 Mar; 79(9-10):1428-36. PubMed ID: 10188886
[TBL] [Abstract][Full Text] [Related]
25. Changing costs of metastatic non small cell lung cancer in the Netherlands.
Keusters WR; de Weger VA; Hövels A; Schellens JHM; Frederix GWJ
Lung Cancer; 2017 Dec; 114():56-61. PubMed ID: 29173766
[TBL] [Abstract][Full Text] [Related]
26. [The human and economic burden of cancer in France in 2014, based on the Sniiram national database].
Tuppin P; Pestel L; Samson S; Cuerq A; Rivière S; Tala S; Denis P; Drouin J; Gissot C; Gastaldi-Ménager C; Fagot-Campagna A
Bull Cancer; 2017 Jun; 104(6):524-537. PubMed ID: 28285755
[TBL] [Abstract][Full Text] [Related]
27. Health system costs of metastatic breast cancer.
Wai ES; Trevisan CH; Taylor SCM ; Mates D; Jackson JS; Olivotto IA
Breast Cancer Res Treat; 2001 Feb; 65(3):233-40. PubMed ID: 11336245
[TBL] [Abstract][Full Text] [Related]
28. Estimates of the lifetime costs of breast cancer treatment in Canada.
Will BP; Berthelot JM; Le Petit C; Tomiak EM; Verma S; Evans WK
Eur J Cancer; 2000 Apr; 36(6):724-35. PubMed ID: 10762744
[TBL] [Abstract][Full Text] [Related]
29. Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands.
Schneider PP; Ramaekers BL; Pouwels X; Geurts S; Ibragimova K; de Boer M; Vriens B; van de Wouw Y; den Boer M; Pepels M; Tjan-Heijnen V; Joore M
Value Health; 2021 May; 24(5):668-675. PubMed ID: 33933235
[TBL] [Abstract][Full Text] [Related]
30. [Breast Cancer: Value-Based Healthcare, Costs and Financing].
Harfouche A; Silva S; Faria J; Araújo R; Gouveia A; Lacerda M; D'Orey L
Acta Med Port; 2017 Nov; 30(11):762-768. PubMed ID: 29279067
[TBL] [Abstract][Full Text] [Related]
31. A model for estimating the costs and burdens of breast cancer diagnosis and treatment in Canada.
Will BP; Berthelot JM; Houle C; Verma S; Tomiak E; Evans WK
Health Rep; 1993; 5(4):399-408. PubMed ID: 8011960
[TBL] [Abstract][Full Text] [Related]
32. Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment).
Fernandes J; Bregman B; Combemale P; Amaz C; de Léotoing L; Vainchtock A; Gaudin AF
BMC Health Serv Res; 2017 Aug; 17(1):542. PubMed ID: 28789648
[TBL] [Abstract][Full Text] [Related]
33. Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis.
Karnon J; Kerr GR; Jack W; Papo NL; Cameron DA
Br J Cancer; 2007 Aug; 97(4):479-85. PubMed ID: 17653077
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal economic consequences of colorectal cancer in a university hospital setting.
Van Gelder M; Peeters M; Annemans L
Acta Clin Belg; 2013; 68(2):97-100. PubMed ID: 23967716
[TBL] [Abstract][Full Text] [Related]
35. Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium.
Frederix GW; Severens JL; Hövels AM; van Hasselt JG; Hooiveld MJ; Neven P; Raaijmakers JA; Schellens JH
Eur J Cancer Care (Engl); 2015 May; 24(3):340-54. PubMed ID: 25413216
[TBL] [Abstract][Full Text] [Related]
36. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.
Kandel M; Allayous C; Dalle S; Mortier L; Dalac S; Dutriaux C; Leccia MT; Guillot B; Saiag P; Lacour JP; Legoupil D; Lesimple T; Aubin F; Beylot-Barry M; Brunet-Possenti F; Arnault JP; Granel-Brocard F; Stoebner PE; Dupuy A; Maubec E; Grob JJ; Dreno B; Rotolo F; Ballon A; Michiels S; Lebbe C; Borget I
Eur J Cancer; 2018 Dec; 105():33-40. PubMed ID: 30384014
[TBL] [Abstract][Full Text] [Related]
37. Costs of colorectal cancer in different states of the disease.
Färkkilä N; Torvinen S; Sintonen H; Saarto T; Järvinen H; Hänninen J; Taari K; Roine RP
Acta Oncol; 2015 Apr; 54(4):454-62. PubMed ID: 25519708
[TBL] [Abstract][Full Text] [Related]
38. Absenteeism and indirect costs during the year following the diagnosis of an operable breast cancer: A prospective multicentric cohort study.
Ferrier C; Thebaut C; Levy P; Baffert S; Asselain B; Rouzier R; Hequet D
J Gynecol Obstet Hum Reprod; 2021 Jun; 50(6):101871. PubMed ID: 32673814
[TBL] [Abstract][Full Text] [Related]
39. Cost of treatment for breast cancer in central Vietnam.
Hoang Lan N; Laohasiriwong W; Stewart JF; Tung ND; Coyte PC
Glob Health Action; 2013 Feb; 6():18872. PubMed ID: 23394855
[TBL] [Abstract][Full Text] [Related]
40. Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study.
Héquet D; Huchon C; Soilly AL; Asselain B; Berseneff H; Trichot C; Combes A; Alves K; Nguyen T; Rouzier R; Baffert S
PLoS One; 2019; 14(7):e0210917. PubMed ID: 31291250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
